Campbell & Co Investment Adviser’s Aratana Therapeutics, Inc. PETX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-11,444	Closed	-$41K	–	780
2019 Q1	$41K	Sell	11,444 -1,546	-12%	-$6.7K	0.02%	496
2018 Q4	$88K	Buy	+12,990	New	+$79.3K	0.09%	308
2018 Q3	–	Sell	-21,581	Closed	-$92K	–	585
2018 Q2	$92K	Buy	21,581 +9,449	+78%	+$47.6K	0.07%	351
2018 Q1	$54K	Buy	12,132 +890	+8%	+$3.97K	0.05%	342
2017 Q4	$59K	Buy	+11,242	New	+$68.8K	0.04%	377

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OAC

OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Campbell & Co Investment Adviser's PETX Position: Q2 2019 in Review

Campbell & Co Investment Adviser sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 11,444 shares — an estimated $41K sold.

Campbell & Co Investment Adviser first reported a position in PETX in Q4 2017 and held it in 5 quarters. The position peaked at $92K in Q2 2018. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

Campbell & Co Investment Adviser reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Campbell & Co Investment Adviser sold 11,444 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $41K.
Campbell & Co Investment Adviser first reported a position in Aratana Therapeutics, Inc. in Q4 2017 and held it in 5 quarters.
Campbell & Co Investment Adviser's Aratana Therapeutics, Inc. position peaked at $92K in Q2 2018.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2019, filed 10 Jul 2019.